Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring

Blood. 2008 Oct 15;112(8):3057-64. doi: 10.1182/blood-2008-05-160176. Epub 2008 Aug 1.

Abstract

The clinical characteristics and prognosis remain unclear for nasal-type NK/T-cell lymphoma of Waldeyer ring (WR-NKTL). The aim of this study is to determine the clinical features and outcome. Ninety-one patients with WR-NKTL were reviewed. According to the Ann Arbor system, 15, 56, 12, and 8 patients had stage I, II, III, and IV. Of patients with stage I and II, 54 received combined chemotherapy and radiotherapy (CMT), 13 received radiotherapy alone, and 4 patients received chemotherapy alone. All 20 patients with stage III/IV received primary chemotherapy. The disease is characterized by predominance in young males, good performance, a propensity for nodal involvement, frequent stage II through IV diseases, low frequency of elevated LDH, low-risk international prognostic index (IPI), high sensitivity to radiotherapy, and intermediate sensitivity to chemotherapy. The 5-year overall survival and progression-free survival for all patients were 65% and 51%, respectively. The age, B symptoms, stage, and IPI were important prognostic factors. CMT tended to improve the survival compared with radiotherapy alone for patients with stage I and II diseases. Both nodal involvement and distant extranodal dissemination were the primary failure patterns. WR-NKTL appears to have distinct clinical characteristics and favorable outcomes.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use
  • Child
  • Combined Modality Therapy
  • Disease-Free Survival
  • Female
  • Humans
  • Killer Cells, Natural / cytology*
  • Lymphoma, T-Cell / diagnosis*
  • Lymphoma, T-Cell / drug therapy*
  • Lymphoma, T-Cell / radiotherapy*
  • Male
  • Middle Aged
  • Nose Neoplasms / diagnosis*
  • Nose Neoplasms / drug therapy*
  • Nose Neoplasms / radiotherapy*
  • Prognosis
  • Treatment Outcome

Substances

  • Antineoplastic Agents